NCT04551573 - A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects | Biotech Hunter

Timeline

Start Date

May 31, 2021

Primary Completion Date

October 31, 2021

Study Completion Date

November 30, 2021

Conditions

TuberculosisHiv

Interventions

DRUG

Rifapentine daily

In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)

DRUG

Rifapentine weekly

In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)

Trial Locations (1)

06520

Yale New Haven Hospital, New Haven